Tg Therapeutics (TGTX) EBITDA (2011 - 2026)

Tg Therapeutics' EBITDA history runs 16 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• On a quarterly basis, EBITDA rose 303.56% year-over-year to $34.8 million in Q1 2026; TTM through Mar 2026 was $149.5 million, a 149.91% increase from a year earlier, with the FY2025 full-year figure at $123.3 million, up 194.13% from the prior year.
• EBITDA retreated to $34.8 million in Q1 2026 per TGTX's latest filing, from $50.5 million in the prior quarter.
• Across five years, EBITDA topped out at $114.8 million in Q3 2023 and bottomed at -$77.5 million in Q4 2022.
• The 5-year median for EBITDA is $8.6 million (2025), against an average of $139176.5.
• Across the five-year window, EBITDA jumped 428.3% in 2023 and tumbled 89.17% in 2024, its largest moves.
• Year by year, EBITDA stood at -$77.5 million in 2022, then surged by 83.9% to -$12.5 million in 2023, then jumped by 339.88% to $29.9 million in 2024, then soared by 68.6% to $50.5 million in 2025, then slumped by 31.09% to $34.8 million in 2026.
• Per Business Quant, the three latest TGTX EBITDA figures stand at $34.8 million (Q1 2026), $50.5 million (Q4 2025), and $29.4 million (Q3 2025).